Journal profile · Immunology and Microbiology-Immunology
Immunotherapy Advances
ISSN 2732-4303 · Oxford University Press · United Kingdom
Immunotherapy Advances: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 7.6 (journal website); fully open access; APC charged, amount not published; median 109 days to acceptance (59 articles, last 24 months); 24 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Immunotherapy Advances is published by Oxford University Press and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Immunotherapy and Immune Responses, CAR-T cell therapy research and Immune Cell Function and Interaction, together about 43.4% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Immunotherapy Advances publishes scientifically rigorous research relating to manipulations of the immune system for the benefit of human and animal health in all disease areas. The journal covers the translational pipeline for immunotherapy from discovery research and preclinical animal models through to clinical trials. Experimental medicine and first-in-human clinical studies are encouraged, and negative clinical trials are welcomed where they contribute to immune-mechanistic insight. We also recognise the growing importance of interdisciplinary working in this area and encourage studies that are at the interface with engineering, mathematics and computer science, chemistry and the physical sciences. Topics of interest to the journal include: Manipulations of the immune system for the benefit of human and animal health Immunotherapeutic interventions (such as small molecules, biotherapeutics and therapeutic vaccines) and their mechanism of action in all disease areas Understanding of immunological mechanisms Discovery research through to clinical trials Interdisciplinary research with physical sciences, maths and engineering Authors should refer to the author guidelines for details on peer review, article types and the submission process.
From the journal's Aims & Scope
Research area (LetPub): Immunology and Microbiology-Immunology
Editor-in-chief Tim Elliott FRSBPublisher website
Editorial board by country: 3 in mainland China (about 18%); most named Netherlands 5, United Kingdom 4, Mainland China 3, United States 2, Germany 1 (17 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immunotherapy and Immune ResponsesImmunology and Microbiology15.5%
- CAR-T cell therapy researchMedicine14.8%
- Immune Cell Function and InteractionImmunology and Microbiology13.2%
- Cancer Immunotherapy and BiomarkersMedicine12.5%
- T-cell and B-cell ImmunologyImmunology and Microbiology7.2%
- Monoclonal and Polyclonal Antibodies ResearchMedicine4.9%
- Immune cells in cancerImmunology and Microbiology4%
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology2.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePMCPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 7.6Publisher website ·
- 5-year impact factor (publisher) 2025
- 4.6Publisher website ·
- CiteScore 2026-06
- 7.6LetPub ·
- CiteScore (publisher) 2025
- 7.6Publisher website ·
- SJR 2026-06
- 1.5LetPub ·
- SNIP 2026-06
- 1.09LetPub ·
- h-index
- 25OpenAlex ·
- i10-index
- 57OpenAlex ·
- 2-year mean citedness
- 3.28OpenAlex ·
- Self-citation rate
- 2.3%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 31LetPub ·
- Downloads per year (publisher) 2025
- 76,984Publisher website ·
Articles by year OpenAlex count · 162 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 3 | 3 | 0 |
| 2025 | 24 | 24 | 6 |
| 2024 | 42 | 42 | 220 |
| 2023 | 32 | 32 | 390 |
| 2022 | 23 | 23 | 449 |
| 2021 | 27 | 27 | 632 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
109 daysMedian, submission to acceptance · P25–P75 86 days – 140 days
- Acceptance to online
- median 9 days (59 articles)
- Submission to online
- median 133 days
- Sample
- 59 articles with submission and acceptance dates (60 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 7 weeksLetPub ·
- Submission to first decision 2025
- 40.5 daysPublisher website ·
- Submission to publication (journal-reported)
- about 7 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | GBP 2,205 | Yes | CC BY, CC BY-NC | |
| OpenAlex | GBP 2,315 | — | — | |
| LetPub | GBP 2,205 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Oxford University Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2732-4303
- Society / sponsor
- British Society for Immunology
- Latest issue on the website
- Volume 6, Issue 1 (2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Immunotherapy Advances
What CAS zone is Immunotherapy Advances in?
In the 2025 upgraded edition of the CAS Journal Ranking, Immunotherapy Advances is in Zone 4 of Medicine, and in Zone 4 of the minor category Immunology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Immunotherapy Advances?
The journal's website gives an impact factor of 7.6 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 7.6, h-index 25.
How long does peer review take at Immunotherapy Advances?
Based on the dates recorded on 59 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 109 days (interquartile range 86–140 days); authors report an average review time of about 7 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Immunotherapy Advances based?
Of the 17 board members whose country the journal's board page names, 3 (about 18%) are in mainland China; the countries named most often are Netherlands (5), United Kingdom (4) and Mainland China (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Immunotherapy Advances?
According to LetPub and DOAJ records, Immunotherapy Advances is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Web of Science and PMC; that list has not been checked against each database.
Is Immunotherapy Advances open access, and what is the APC?
Immunotherapy Advances is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .